Max Topp

Max Topp at University Hospital Wurzburg has been central to the clinical development of blinatumomab (Blincyto), the first FDA-approved BiTE antibody for B-cell acute lymphoblastic leukemia. His pivotal TOWER and BLAST trial work established blinatumomab for relapsed/refractory ALL and MRD-positive disease respectively. He has contributed to understanding the mechanisms of blinatumomab resistance including antigen loss and immune exhaustion. His work opened the clinical BiTE era that has now expanded to CD3-engaging bispecifics across multiple malignancies.